Das AIP-Protokoll – fördert es die Behandlung von Autoimmunerkrankungen?

Autoimmune disorders constitute a category of pathological conditions characterized by aberrant immune system activity, wherein self-tolerant mechanisms fail, leading the body’s defense systems to misidentify native, healthy cells and tissues as exogenous threats. This immunological dysfunction triggers a sustained inflammatory cascade, resulting in progressive cellular damage, organ dysfunction, and systemic clinical manifestations. Prominent examples within this nosological group include: chronic lymphocytic thyroiditis (Hashimoto’s thyroiditis), autoimmune hyperthyroidism with associated orbitopathy (Graves’ disease), insulin-dependent diabetes mellitus (type 1 diabetes), gluten-sensitive enteropathy (celiac disease), seropositive chronic polyarthritis (rheumatoid arthritis), demyelinating disease of the central nervous system (multiple sclerosis), systemic lupus erythematosus, and granulomatous inflammation of the gastrointestinal tract of unclear etiology (Crohn’s disease). Clinical sequelae encompass persistent inflammatory states, cumulative structural damage to tissues, and a heterogeneous array of nonspecific symptoms, such as debilitating fatigue, arthralgia, cutaneous manifestations, and gastrointestinal disturbances. Therapeutic paradigms prioritize immunological modulation via immunosuppressive pharmacotherapy alongside symptomatic management. Adjunctive measures may incorporate personalized nutritional interventions, including elimination-based dietary protocols such as the Autoimmune Protocol (AIP), though further clinical validation of their efficacy remains necessary. It is critical to emphasize that current medical science does not provide curative solutions for these conditions; the primary objectives of treatment remain the induction of sustained remission and the mitigation of disease progression alongside associated symptomatology (as delineated in the research by Wang et al., 2015).